The Netherlands: Sander van Deventer takes on CEO role at VectorY

Sander van Deventer, CEO, VectorY

VectorY Therapeutics, a biotech company developing vectorized antibody approaches for the treatment of neurodegenerative diseases, has appointed Sander van Deventer, co-founder and formerly Chief Technology Officer (CTO), as CEO. Van Deventer has 25 years of experience in drug development and a longstanding track record in antibody and gene therapy development. He succeeds Alexander Vos, who…

You must be a HMI Subscriber to view this content.

Subscribe Now »